You've just added:

Home / News

Press Releases

May 17, 2024

The Oxford-Harrington Rare Disease Centre Announces Newly Funded Grant Award Programmes to Develop New Therapies for Friedreich’s Ataxia

The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership (between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio) aimed at driving cutting-edge rare disease breakthroughs, is pleased to announce that it has received a philanthropic donation of up to £650,000... Continue Reading

April 16, 2024

Harrington Discovery Institute Announces 2024 Scholar-Innovator Award Recipients

10 physician-scientists have been selected for drug development grant to advance discoveries into the clinic Continue Reading

March 19, 2024

International Harrington Prize Awarded to Dr. Arlene Sharpe

2024 Harrington Prize for Innovation in Medicine Recognizes Pioneering Work in Immunology Continue Reading

February 08, 2024

The Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute to Support Promising New Drug Development Addressing the Biology of Aging Among People with Alzheimer’s Disease

Dr. Paul Tesar of Case Western Reserve University and Dr. Donald F. Weaver of University Health Network selected for their work targeting novel pathways in Alzheimer’s Continue Reading

February 06, 2024

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

New Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading

January 03, 2024

Jonathan Stamler, MD, Named Fellow of the 2023 National Academy of Inventors

Co-founder and president of Harrington Discovery Institute at University Hospitals receives highest professional distinction awarded solely to inventors Continue Reading

December 21, 2023

Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults

The study showed that all doses of ALX-001 were well tolerated, up to and including levels high enough to achieve full brain target engagement, supporting the company’s plans to continue clinical development for the treatment of Alzheimer’s disease. Continue Reading

November 30, 2023

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading

October 25, 2023

Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Dis

ABX1100 is a first-in-class molecule representing a new approach to reducing toxic levels of glycogen that build up in muscles of patients with Pompe Disease. Continue Reading

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.